Novavax Outlook: Why NVAX Stock Could 12X in the Next 12 Months

1
1
Favorite

Novavax Outlook: Why NVAX Stock Could 12X in the Next 12 Months

InvestorPlace2023-04-13

Recent, positive clinical data released by Novavax (NVAX) indicates that NVAX stock could surge almost 12 times in the next year.The company’s drugs could attain meaningful shares of the Covid-19 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

LianHin
·2023-04-15
Thamk you
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2327189187?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-04-13 00:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2327189187","market":"fut","top_or_hot":-1,"title":"Novavax Outlook: Why NVAX Stock Could 12X in the Next 12 Months","media":"InvestorPlace","content":"<div>\n<p>Recent, positive clinical data released by Novavax (NVAX) indicates that NVAX stock could surge almost 12 times in the next year.The company’s drugs could attain meaningful shares of the Covid-19 ...</p>\n\n<a href=\"https://investorplace.com/2023/04/novavax-outlook-why-nvax-stock-could-12x-in-the-next-12-months/\">Source Link</a>\n\n</div>\n","source":"investorplace","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Outlook: Why NVAX Stock Could 12X in the Next 12 Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Outlook: Why NVAX Stock Could 12X in the Next 12 Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-13 00:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2023/04/novavax-outlook-why-nvax-stock-could-12x-in-the-next-12-months/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recent, positive clinical data released by Novavax (NVAX) indicates that NVAX stock could surge almost 12 times in the next year.The company’s drugs could attain meaningful shares of the Covid-19 ...</p>\n\n<a href=\"https://investorplace.com/2023/04/novavax-outlook-why-nvax-stock-could-12x-in-the-next-12-months/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://investorplace.com/2023/04/novavax-outlook-why-nvax-stock-could-12x-in-the-next-12-months/","article_id":"2327189187","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2327189187","pubTimestamp":1681317323,"columns":[],"sourceInfo":{"source_id":"investorplace","name":"InvestorPlace"},"weMediaInfo":null,"summary":"Recent, positive clinical data released by Novavax (NVAX) indicates that NVAX stock could surge almo","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4568":"美国抗疫概念","BK4588":"碎股","BK4007":"制药","NVAX":"诺瓦瓦克斯医药","HRMY":"Harmony Biosciences Holdings, Inc.","BK4585":"ETF&股票定投概念"},"translate_title":"诺瓦瓦克斯展望：为什么NVAX股票在未来12个月能涨12倍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HRMY":1,"NVAX":1},"content_text":"Recent, positive clinical data released by Novavax (NVAX) indicates that NVAX stock could surge almost 12 times in the next year.The company’s drugs could attain meaningful shares of the Covid-19 vaccine and flu shot markets.NVAX stock could easily undergo a huge short squeeze. \n\n\n\n \n\nSource: Ascannio/Shutterstock.com\n\n\n\nAfter recently reporting strong clinical data, Novavax (NASDAQ:NVAX) has tremendous opportunities in front of it. More specifically, the company’s coronavirus booster and its coronavirus-flu combination vaccine can become huge revenue generators. Given these points, I believe that NVAX stock can soar almost 12 times within the next year.\nThe company’s new CEO also makes me very upbeat about the stock’s outlook. Moreover, the NVAX stock has a very high short interest, and a strong rebound is underway.\n\n\n\nNVAX\nNovavax\n$9.07\n\n\n\n\n\n\n\n\n\nStrong Clinical Data Gives Novavax a Huge Opportunity\nData unveiled by Novavax on April 5 showed that a single booster dose of its Covid-19 shot generated “immune responses [that] were comparable to three total doses of the approved messenger RNA (mRNA) vaccines. “\nThe fact that one dose of Novavax’s vaccine generated a “comparable” response to three shots of the mRNA vaccines should lead some doctors to recommend that their patients get Novavax’s vaccine instead of the mRNA jabs.\nMeanwhile, data indicate that high percentages of the populations of other developed countries have yet to receive boosters. For example, in the U.S., as of last month, only 34 boosters had been administered per 100 people. In the U.K., that figure is 60, in France, it’s 71, and in Germany, it’s 78.\nRemember that if the entire population had received three booster shots each, 300 booster shots per 100 people would be administered.\nRegarding Novavax’s combined flu-Covid vaccine, the company reported that the job had elicited effective responses against both the coronavirus and “and multiple influenza strains.,” PharmaLive.com said.\nMoreover, the combination shot was as safe as taking Novavax’s flu shot and coronavirus jab separately.\n\n\n\n\n\n\nWhy NVAX Stock Can Soar Almost 12 Times\nAccording to Statista, global revenue from the coronavirus vaccine is expected to reach $26 billion next year. Let’s say that Novavax gets 15% of that revenue. That equates to $3.9 billion.\nMeanwhile, revenue from flu vaccines came in at $4.28 billion in 2022. Let’s say the market grows to $4.5 billion next year, and Novavax gets 10% of that revenue. That works out to another $450 million.\nIf the drug maker meets these forecasts and gets a price-sales ratio of just two, its market capitalization would be $8.7 billion. That’s nearly 12 times its current market capitalization of $729 million.\nBut to make this forecast a reality, the company has to greatly step up its marketing efforts, both to doctors and consumers. It remains to be seen if it can do so. Still, with the firm under the leadership of a new, highly accomplished CEO, John Jacobs, I think it may indeed be able to do what’s necessary on the marketing front to at least come close to meeting my projections.\n\n\n\n\n\n\nThree Other Reasons to Be Bullish on NVAX Stock\nSpeaking of the company’s new CEO, Jacobs, as I wrote earlier, has an excellent resume. Specifically, he was CEO of Harmony Biosciences (NASDAQ:HRMY) from 2018 until the beginning of 2023. During his tenure, Harmony launched a successful IPO in 2020, and its stock price climbed from $35 when it started trading to $53 just before it was announced that Jacobs was leaving.\nAlso, during his stint as CEO, the FDA approved the company’s narcolepsy treatment, Wakix. While a short seller has recently alleged that Harmony covered up the deaths of 12 patients who were taking the drug during clinical trials of the treatments, investment bank Raymond James, as well as Harmony itself, have denied the charges, with the bank writing that “Wakix’s safety profile is not an issue based on our own diligence with prescribers.” Moreover, Goldman Sachs recently named Harmony one of the stocks it believes are best positioned to avoid a recession.\nIn any event, the fact that Jacobs would choose to become CEO of Novavax after his successful tenure at Harmony suggests that Novavax’s prospects are strong. Moreover, Jacobs’ experience should be an asset for Novavax and NVAX stock going forward.\nAlso positive for the shares are its high short interest (nearly 40% of NVAX stock was being sold short as of April 6) and the fact that the Street seems to have viewed the data the company released on April 5 positively. As evidence of the latter point, NVAX stock jumped from $7.34 as of the close of trading on April 4 to $8.46 as of the market close on April 6.\nAs of the date of publication, Larry Ramer owned shares of NVAX. He may purchase shares of Eisai during the week of April 10. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.\n\nLarry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been PLUG, XOM and solar stocks. You can reach him on Stocktwits at @larryramer.\n\n\nBiotech, Healthcare, Technology\n\n\nUndervalued Stocks\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubmit\n\n\n\n\n\n\n\nArticle printed from InvestorPlace Media, https://investorplace.com/2023/04/novavax-outlook-why-nvax-stock-could-12x-in-the-next-12-months/.\n©2023 InvestorPlace Media, LLC\n\n\n\n\nSponsored Headlines","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9945423291,"gmtCreate":1681558276214,"gmtModify":1681558279839,"author":{"id":"3572377913685934","authorId":"3572377913685934","name":"LianHin","avatar":"https://static.tigerbbs.com/0564df9bae4cecc584f8ca74257d30c3","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3572377913685934","authorIdStr":"3572377913685934"},"htmlText":"Thamk you","listText":"Thamk you","text":"Thamk you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9945423291","repostId":2327189187,"repostType":2,"repost":{"id":"2327189187","kind":"highlight","pubTimestamp":1681317323,"share":"https://ttm.financial/m/news/2327189187?lang=&edition=fundamental","pubTime":"2023-04-13 00:35","market":"us","language":"en","title":"Novavax Outlook: Why NVAX Stock Could 12X in the Next 12 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2327189187","media":"InvestorPlace","summary":"Recent, positive clinical data released by Novavax (NVAX) indicates that NVAX stock could surge almo","content":"<html><body><div>\n<div>\n<ul><li>Recent, positive clinical data released by <strong>Novavax</strong> (<span><strong><u>NVAX</u></strong></span>) indicates that NVAX stock could surge almost 12 times in the next year.</li><li>The company’s drugs could attain meaningful shares of the Covid-19 vaccine and flu shot markets.</li><li>NVAX stock could easily undergo a huge short squeeze.</li></ul> </div>\n<div></div>\n<figure>\n<div>\n<img decoding=\"async\" height=\"432\" sizes=\"(max-width: 768px) 100vw, 768px\" src=\"https://investorplace.com/wp-content/uploads/2020/03/nvax-stock-1-768x432.jpg\" srcset=\"https://investorplace.com/wp-content/uploads/2020/03/nvax-stock-1-768x432.jpg 768w, https://investorplace.com/wp-content/uploads/2020/03/nvax-stock-1-300x169.jpg 300w, https://investorplace.com/wp-content/uploads/2020/03/nvax-stock-1-1024x576.jpg 1024w, https://investorplace.com/wp-content/uploads/2020/03/nvax-stock-1-200x113.jpg 200w, https://investorplace.com/wp-content/uploads/2020/03/nvax-stock-1-400x225.jpg 400w, https://investorplace.com/wp-content/uploads/2020/03/nvax-stock-1-116x65.jpg 116w, https://investorplace.com/wp-content/uploads/2020/03/nvax-stock-1-100x56.jpg 100w, https://investorplace.com/wp-content/uploads/2020/03/nvax-stock-1-89x50.jpg 89w, https://investorplace.com/wp-content/uploads/2020/03/nvax-stock-1-78x44.jpg 78w, https://investorplace.com/wp-content/uploads/2020/03/nvax-stock-1.jpg 1600w\" width=\"768\"/> </div>\n<figcaption>\n<p>Source: Ascannio/Shutterstock.com</p>\n</figcaption>\n</figure>\n<div>\n<p><span>After recently reporting strong clinical data, </span><strong><span>Novavax </span></strong><span>(NASDAQ:</span><strong><u><span>NVAX</span></u></strong><span>) has tremendous opportunities in front of it. More specifically, the company’s coronavirus booster and its coronavirus-flu combination vaccine can become huge revenue generators. Given these points, I believe that NVAX stock can soar almost 12 times within the next year.</span></p>\n<p><span>The company’s new CEO also makes me very upbeat about the stock’s outlook. Moreover, the NVAX stock has a very high short interest, and a strong rebound is underway.</span></p>\n<table border=\"1\">\n<tbody>\n<tr>\n<td><strong>NVAX</strong></td>\n<td>Novavax</td>\n<td>$9.07</td>\n</tr>\n</tbody>\n</table>\n<div>\n<div>\n<div></div>\n<div></div>\n</div>\n</div>\n<h2>Strong Clinical Data Gives Novavax a Huge Opportunity</h2>\n<p><span>Data unveiled by Novavax on April 5 </span><span>showed that a</span><span> single booster dose of its Covid-19 shot generated “immune responses [that] were comparable to three total doses of the approved messenger RNA (mRNA) vaccines. “</span></p>\n<p><span>The fact that one dose of Novavax’s vaccine generated a “comparable” response to three shots of the mRNA vaccines should lead some doctors to recommend that their patients get Novavax’s vaccine instead of the mRNA jabs.</span></p>\n<p><span>Meanwhile, data indicate that high percentages of the populations of other developed countries have yet to receive boosters. For example, in the U.S., </span><span>as of last month</span><span>, only 34 boosters had been administered per 100 people. In the U.K., that figure is 60, in France, it’s 71, and in Germany, it’s 78.</span></p>\n<p><span>Remember that if the entire population had received three booster shots each, 300 booster shots per 100 people would be administered.</span></p>\n<p><span>Regarding Novavax’s combined flu-Covid vaccine, the company </span><span>reported that</span><span> the job had elicited effective responses against both the coronavirus and “and multiple influenza strains.,” </span><em><span>PharmaLive.com</span></em><span> said.</span></p>\n<p><span>Moreover, the combination shot was as safe as taking Novavax’s flu shot and coronavirus jab separately.</span></p>\n<div>\n<div>\n<div></div>\n<div></div>\n</div>\n</div>\n<h2>Why NVAX Stock Can Soar Almost 12 Times</h2>\n<p><span>According to </span><em><span>Statista</span></em><span>, global revenue from the coronavirus </span><span>vaccine is expected</span><span> to reach $26 billion next year. Let’s say that Novavax gets 15% of that revenue. That equates to $3.9 billion.</span></p>\n<p><span>Meanwhile, revenue from flu vaccines came in at $4.28 billion in 2022. Let’s say the market grows to $4.5 billion next year, and Novavax gets 10% of that revenue. That works out to another $450 million.</span></p>\n<p><span>If the drug maker meets these forecasts and gets a price-sales ratio of just two, its market capitalization would be $8.7 billion. That’s nearly 12 times its current market capitalization of $729 million.</span></p>\n<p><span>But to make this forecast a reality, the company has to greatly step up its marketing efforts, both to doctors and consumers. It remains to be seen if it can do so. Still, with the firm under the leadership of a new, highly accomplished CEO, John Jacobs, I think it may indeed be able to do what’s necessary on the marketing front to at least come close to meeting my projections.</span></p>\n<div>\n<div>\n<div></div>\n<div></div>\n</div>\n</div>\n<h2>Three Other Reasons to Be Bullish on NVAX Stock</h2>\n<p><span>Speaking of the company’s new CEO, Jacobs, as I wrote earlier, has an excellent resume. Specifically, he was CEO of </span><strong><span>Harmony Biosciences </span></strong><span>(NASDAQ:</span><strong><u><span>HRMY</span></u></strong><span>) from 2018 until the beginning of 2023. During his tenure, Harmony launched a successful IPO in 2020, and its stock price climbed from $35 when it started trading to $53 just before it was announced that Jacobs was leaving.</span></p>\n<p><span>Also, during his stint as CEO, the FDA approved the company’s narcolepsy treatment, Wakix. While a short seller </span><span>has recently alleged</span><span> that Harmony covered up the deaths of 12 patients who were taking the drug during clinical trials of the treatments, investment bank </span>Raymond James<span>, as well as Harmony itself, have denied the charges, </span><span>with the bank writing</span><span> that “Wakix’s safety profile is not an issue based on our own diligence with prescribers.” Moreover, </span>Goldman Sachs<span> recently named Harmony one of the stocks it believes are best positioned to avoid a recession.</span></p>\n<p><span>In any event, the fact that Jacobs would choose to become CEO of Novavax after his successful tenure at Harmony suggests that Novavax’s prospects are strong. Moreover, Jacobs’ experience should be an asset for Novavax and NVAX stock going forward.</span></p>\n<p><span>Also positive for the shares are its high short interest (nearly 40% of NVAX stock was being sold short </span><span>as of</span><span> April 6) and the fact that the Street seems to have viewed the data the company released on April 5 positively. As evidence of the latter point, NVAX stock jumped from $7.34</span><span> </span><span>as of the close of</span><span> trading on April 4 to $8.46 as of the market close on April 6.</span></p>\n<p><em>As of the date of publication, Larry Ramer owned shares of NVAX. He may purchase shares of Eisai during the week of April 10. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.</em></p>\n<div>\n<p>Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been PLUG, XOM and solar stocks. You can reach him on Stocktwits at @larryramer.</p>\n</div>\n<div>\n<p>Biotech, Healthcare, Technology</p>\n</div>\n<div>\n<p>Undervalued Stocks</p>\n</div>\n<div>\n<div>\n<div></div>\n<div></div>\n</div>\n</div>\n</div>\n<div>\n<div hidden=\"true\">\n<div>\n<svg fill=\"none\" height=\"32\" viewbox=\"0 0 261 32\" width=\"261\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M38.8652 7.49652H42.2492V25.7517H38.8652V7.49652ZM60.0112 7.49652H63.3142V25.7517H60.0921L50.9278 13.1733V25.7517H47.6248V7.49652H50.8469L60.0112 20.0749V7.49652ZM66.5201 7.49652H70.2279L75.4578 21.8955L80.7685 7.49652H84.3144L77.1417 25.7517H73.5957L66.5201 7.49652ZM87.4232 7.49652H100.457V10.5418H90.8072V15.0601H99.5019V18.1054H90.8072V22.7064H100.781V25.7517H87.4232V7.49652ZM113.637 10.8563C112.666 10.5253 111.872 10.3598 111.063 10.3598C110.253 10.3598 109.622 10.5253 109.136 10.8563C108.65 11.1873 108.407 11.601 108.407 12.1803C108.407 12.6768 108.569 13.0906 108.893 13.4216C109.217 13.7526 109.622 14.0009 110.188 14.2491C110.674 14.4974 111.403 14.7456 112.196 14.9939C113.41 15.3249 114.366 15.7387 115.175 16.0697C115.985 16.4007 116.616 16.98 117.183 17.7082C117.75 18.453 117.993 19.3467 117.993 20.5052C117.993 21.6638 117.669 22.5575 117.102 23.385C116.535 24.2125 115.742 24.858 114.689 25.2718C113.637 25.6855 112.52 25.9338 111.144 25.9338C109.767 25.9338 108.407 25.6855 107.047 25.1063C105.752 24.6098 104.554 23.865 103.582 22.9713L105.023 20.0087C105.914 20.8362 106.95 21.4817 108.083 21.9782C109.217 22.4747 110.253 22.723 111.225 22.723C112.196 22.723 112.908 22.5575 113.475 22.1437C114.042 21.73 114.285 21.2334 114.285 20.588C114.285 20.0915 114.123 19.5949 113.799 19.2639C113.475 18.9329 113.07 18.6847 112.504 18.4364C112.018 18.1882 111.289 18.0226 110.415 17.6916C109.201 17.3606 108.245 16.9469 107.436 16.6159C106.626 16.2848 105.995 15.7056 105.509 15.0601C104.942 14.3153 104.699 13.4216 104.699 12.2631C104.699 11.1873 104.942 10.2936 105.509 9.46603C106.076 8.6385 106.869 8.07578 107.841 7.66202C108.893 7.24826 110.01 7 111.386 7C112.52 7 113.718 7.16551 114.851 7.49652C115.985 7.82753 117.021 8.32404 117.912 8.88676L116.471 12.1803C115.499 11.6838 114.609 11.27 113.637 10.8563ZM120.146 7.49652H134.702V10.6246H129.148V25.7517H125.683V10.608H120.13V7.49652H120.146ZM149.987 8.473C151.428 9.30052 152.561 10.4425 153.452 11.8493C154.261 13.2395 154.747 14.8946 154.747 16.6159C154.747 18.3371 154.342 19.9094 153.452 21.3824C152.642 22.7726 151.444 23.9312 149.987 24.7587C148.546 25.5862 146.926 26 145.162 26C143.397 26 141.778 25.5862 140.337 24.7587C138.896 23.9312 137.762 22.7892 136.872 21.3824C136.062 19.9922 135.576 18.3371 135.576 16.6159C135.576 14.8946 135.981 13.3223 136.872 11.8493C137.681 10.4591 138.879 9.30052 140.337 8.473C141.794 7.64547 143.397 7.23171 145.162 7.23171C146.926 7.23171 148.546 7.66202 149.987 8.473ZM142.182 11.1873C141.211 11.7666 140.499 12.5113 139.932 13.4051C139.365 14.3981 139.122 15.3746 139.122 16.5331C139.122 17.6916 139.365 18.7509 139.932 19.6611C140.499 20.6542 141.227 21.3824 142.182 21.9617C143.073 22.5409 144.109 22.7892 145.243 22.7892C146.295 22.7892 147.331 22.5409 148.222 21.9617C149.112 21.3824 149.825 20.6376 150.391 19.6611C150.958 18.6681 151.201 17.6916 151.201 16.5331C151.201 15.3746 150.958 14.3153 150.391 13.4051C149.825 12.4948 149.096 11.6838 148.222 11.1873C147.331 10.608 146.295 10.3598 145.243 10.3598C144.109 10.3763 143.073 10.608 142.182 11.1873ZM169.773 25.7517L166.712 20.3232H162.049V25.669H158.665V7.49652H166.065C168.396 7.49652 170.161 8.07578 171.456 9.13502C172.752 10.2108 173.302 11.7666 173.302 13.7361C173.302 15.1263 172.978 16.3676 172.412 17.3606C171.764 18.3537 170.971 19.0819 169.756 19.6611L173.691 25.669H169.756L169.773 25.7517ZM161.968 17.2779H165.984C167.279 17.2779 168.234 17.0296 168.963 16.4503C169.611 15.8711 170.015 15.0601 170.015 13.9016C170.015 12.743 169.692 11.9321 168.963 11.4355C168.315 10.8563 167.279 10.608 165.984 10.608H161.968V17.2779ZM190.757 8.90331C191.971 9.97909 192.521 11.4521 192.521 13.3389C192.521 15.3084 191.874 16.8807 190.757 17.9399C189.542 19.0157 187.858 19.5784 185.608 19.5784H180.783V25.5035H179.018V7.34756H185.608C187.777 7.34756 189.542 7.92683 190.757 8.90331ZM189.461 16.8807C190.352 16.0531 190.821 14.9939 190.821 13.4216C190.821 11.9486 190.336 10.8728 189.461 10.0453C188.571 9.21777 187.211 8.88676 185.527 8.88676H180.783V18.0226H185.527C187.211 18.0392 188.506 17.7082 189.461 16.8807ZM197.023 7.34756H198.787V23.9643H206.673V25.6028H197.104V7.34756H197.023ZM224.516 25.6028L222.427 20.7535H212.534L210.445 25.6028H208.599L216.647 7.43031H218.492L226.54 25.6028H224.516ZM213.182 19.115H221.714L217.456 9.25087L213.182 19.115ZM240.286 9.39983C239.315 8.98606 238.359 8.82056 237.388 8.82056C236.028 8.82056 234.732 9.15157 233.599 9.81359C232.466 10.4756 231.51 11.3693 230.863 12.6106C230.215 13.7692 229.81 15.0767 229.81 16.4835C229.81 17.8737 230.134 19.115 230.863 20.3563C231.51 21.5148 232.466 22.4085 233.599 23.1533C234.732 23.8153 236.011 24.2291 237.388 24.2291C238.359 24.2291 239.315 24.0636 240.286 23.6498C241.257 23.2361 242.051 22.7395 242.779 22.0113L243.832 23.1699C242.941 23.9974 241.905 24.6429 240.772 25.1394C239.638 25.6359 238.44 25.8841 237.307 25.8841C235.623 25.8841 234.085 25.4704 232.644 24.6429C231.203 23.8153 230.15 22.6733 229.26 21.2666C228.45 19.8763 228.045 18.304 228.045 16.5828C228.045 14.8615 228.45 13.372 229.341 11.9817C230.15 10.5915 231.267 9.43293 232.725 8.6054C234.166 7.77788 235.704 7.36411 237.388 7.36411C238.602 7.36411 239.719 7.61237 240.853 8.02613C241.986 8.52265 242.941 9.10192 243.832 9.91289L242.779 11.1376C242.051 10.3929 241.241 9.81359 240.286 9.39983ZM248.641 7.34756H260.541V8.98606H250.406V15.4904H259.489V17.1289H250.406V23.9477H260.865V25.5862H248.641V7.34756Z\" fill=\"#212121\"></path>\n<path d=\"M31.3505 14.3755C31.3667 14.6507 31.3829 15.1201 31.2857 15.1687C31.1077 15.1201 30.9458 13.5337 31.1077 13.4365H31.1239C31.2534 13.4689 31.3343 14.0355 31.3505 14.3755Z\" fill=\"#00A000\"></path>\n<path d=\"M16.959 13.1775C16.7485 15.4763 13.8346 16.3343 12.4424 14.505C11.3092 13.0156 12.1996 10.6036 14.4659 10.4902C16.3438 10.6036 17.0561 12.1253 16.959 13.1775Z\" fill=\"#00A000\"></path>\n<path d=\"M14.1103 18.034C14.0456 18.7949 13.4952 20.1223 11.8116 20.2195C9.41565 20.09 8.65479 17.176 10.1441 15.8C10.7269 15.282 11.3421 15.2496 11.6497 15.2334C13.4952 15.3305 14.2075 16.9332 14.1103 18.034Z\" fill=\"#00A000\"></path>\n<path d=\"M21.4764 15.9942C21.4116 16.7875 20.8288 18.1797 19.1128 18.2768C16.555 18.1473 15.9075 15.1686 17.5749 13.7602C18.1901 13.2422 18.8052 13.2098 19.1128 13.1936C21.0069 13.3069 21.5735 14.9743 21.4764 15.9942Z\" fill=\"#00A000\"></path>\n<path d=\"M18.7565 20.6727C18.4004 22.7773 15.6969 23.4248 14.4504 21.7088C13.4952 20.3975 14.1104 18.1311 16.4739 18.0178C18.3356 18.115 18.9184 19.6205 18.7565 20.6727Z\" fill=\"#00A000\"></path>\n<path d=\"M12.1507 10.555C12.0373 11.2349 11.4384 12.4005 9.98138 12.4976C7.90925 12.3843 7.89306 10.0046 9.1072 8.90376C9.68999 8.38572 10.2242 8.35335 10.4832 8.33716C11.9726 8.4181 12.2963 9.74556 12.1507 10.555Z\" fill=\"#00A000\"></path>\n<path d=\"M18.9993 8.758C19.0155 10.4578 16.8462 11.2187 15.5349 9.97214C14.3532 8.85513 14.9521 6.76681 16.8948 6.66968C18.4165 6.76681 18.9831 7.99714 18.9993 8.758Z\" fill=\"#00A000\"></path>\n<path d=\"M23.2892 11.2836C23.3864 13.0157 21.6056 13.8737 20.2458 12.7405C18.805 11.5264 19.2259 9.19524 20.9095 9.01717C20.9581 9.01717 21.039 9.01717 21.1038 9.00098C22.6093 9.09811 23.2407 10.4579 23.2892 11.2836Z\" fill=\"#00A000\"></path>\n<path d=\"M9.34996 15.1687C9.28521 15.8972 8.79955 17.1599 7.4559 17.2409C5.44853 17.1114 5.10857 14.2136 6.53316 13.0642C6.95406 12.7405 7.31021 12.7081 7.55304 12.6919C8.86431 12.7728 9.46328 14.0355 9.34996 15.1687Z\" fill=\"#00A000\"></path>\n<path d=\"M25.0365 18.6978C24.6642 20.608 22.6406 21.3203 21.7017 19.8634C20.8599 18.5521 21.6369 16.3343 23.4015 16.2209C24.8422 16.3181 25.2308 17.7265 25.0365 18.6978Z\" fill=\"#00A000\"></path>\n<path d=\"M11.6007 22.4698C11.633 23.9267 10.1437 24.7847 8.80003 23.603C7.47257 22.4212 7.7154 20.3976 9.22093 20.2196C9.2695 20.2196 9.35044 20.2196 9.4152 20.2034C10.7265 20.2843 11.5683 21.4337 11.6007 22.4698Z\" fill=\"#00A000\"></path>\n<path d=\"M15.8267 24.7199C15.7781 25.2218 15.341 26.1769 14.1269 26.2417C12.4433 26.1607 11.4882 24.1857 12.6052 23.1335C13.0585 22.7126 13.5765 22.6964 13.8031 22.6802C15.1953 22.7449 15.94 23.781 15.8267 24.7199Z\" fill=\"#00A000\"></path>\n<path d=\"M22.1549 23.101C21.6044 24.6713 19.5485 25.3835 18.7715 23.8942C18.1563 22.7286 19.0628 20.9641 20.7303 20.8669C21.8797 20.8831 22.5758 21.9354 22.1549 23.101Z\" fill=\"#00A000\"></path>\n<path d=\"M14.6774 6.50773C14.5965 7.00958 14.0946 7.9647 12.7995 8.02946C11.1807 7.93233 10.9702 6.31347 12.0225 5.32597C12.5567 4.82413 13.0747 4.80794 13.2852 4.79175C14.4184 4.8565 14.7907 5.82781 14.6774 6.50773Z\" fill=\"#00A000\"></path>\n<path d=\"M7.18189 19.9604C7.19808 20.1223 7.26284 21.5631 6.06488 21.6602C4.41365 21.5469 3.71755 18.8758 4.75361 18.0016C5.01263 17.7912 5.25546 17.775 5.41734 17.7588C6.53435 17.8397 7.11714 19.0862 7.18189 19.9604Z\" fill=\"#00A000\"></path>\n<path d=\"M26.9959 13.906C27.0282 15.4601 25.7655 16.3019 24.7457 15.4115C23.5477 14.3593 23.7096 11.8177 25.3123 11.7043C26.3645 11.7691 26.9635 12.8861 26.9959 13.906Z\" fill=\"#00A000\"></path>\n<path d=\"M18.9988 26.7921C18.9826 26.8407 18.5455 27.8929 17.3961 27.9577C16.182 27.8767 15.7611 26.436 16.7 25.5941C17.1695 25.1732 17.6551 25.1571 17.8656 25.1409C19.0635 25.2218 19.2416 26.1446 18.9988 26.7921Z\" fill=\"#00A000\"></path>\n<path d=\"M20.0999 4.92117C20.1808 5.32589 20.0837 6.11913 19.08 6.16769C17.6392 6.08675 16.9755 4.53265 17.7525 3.77179C18.0116 3.52896 18.303 3.51277 18.4325 3.49658C19.3228 3.56134 19.9704 4.37076 20.0999 4.92117Z\" fill=\"#00A000\"></path>\n<path d=\"M8.33073 8.11044C8.15266 8.61229 7.55368 9.55122 6.58237 9.61598C5.33585 9.51884 5.57868 7.80286 6.6795 6.86392C7.16515 6.44302 7.53749 6.42683 7.68319 6.41064C8.54118 6.4754 8.58975 7.44671 8.33073 8.11044Z\" fill=\"#00A000\"></path>\n<path d=\"M5.43276 12.449C5.30325 13.0317 4.86616 14.0516 3.97579 14.1164C2.6807 14.0031 2.8264 11.6557 3.89485 10.7492C4.20243 10.4901 4.42907 10.474 4.59095 10.4578C5.40038 10.5387 5.62702 11.5424 5.43276 12.449Z\" fill=\"#00A000\"></path>\n<path d=\"M24.1468 6.88001C24.5029 7.98083 23.6773 8.66075 22.6251 8.11034C21.4109 7.4628 21.0224 5.58493 22.0423 5.30972C22.107 5.29353 22.2042 5.29353 22.2689 5.27734C23.224 5.3421 23.9363 6.24866 24.1468 6.88001Z\" fill=\"#00A000\"></path>\n<path d=\"M10.0796 26.3387C10.0958 26.3873 10.4196 27.4395 9.5454 27.4881C8.34745 27.4233 7.08474 25.6264 7.78085 24.9789C7.94273 24.817 8.15318 24.8008 8.28269 24.8008C9.20544 24.8493 9.88536 25.7235 10.0796 26.3387Z\" fill=\"#00A000\"></path>\n<path d=\"M27.3692 21.3364C26.916 22.5991 25.5885 23.3438 25.1514 22.3077C24.7143 21.304 25.5237 19.4747 26.7055 19.3938C27.6283 19.4747 27.6444 20.5756 27.3692 21.3364Z\" fill=\"#00A000\"></path>\n<path d=\"M24.245 25.2864C23.5975 26.4034 22.2053 26.9862 21.9463 26.0311C21.7034 25.1569 22.6586 23.7323 23.7917 23.6514C24.6336 23.7161 24.6821 24.5579 24.245 25.2864Z\" fill=\"#00A000\"></path>\n<path d=\"M13.8031 28.1518C13.9003 29.0098 13.0909 29.4631 12.1519 28.7184C11.1644 27.9576 11.3101 26.9377 12.1519 26.8406C12.1843 26.8406 12.2329 26.8406 12.2814 26.8406C13.1394 26.873 13.7384 27.5529 13.8031 28.1518Z\" fill=\"#00A000\"></path>\n<path d=\"M16.4094 3.23778C16.3446 4.22528 14.9848 4.50049 14.4182 3.83676C13.9002 3.20541 14.4668 2.18553 15.3571 2.13696C16.0047 2.15315 16.4418 2.71975 16.4094 3.23778Z\" fill=\"#00A000\"></path>\n<path d=\"M11.3909 4.41948C10.8891 5.55268 9.52923 5.95739 9.18927 5.27747C8.8655 4.59756 9.95013 3.31866 10.9053 3.25391C11.5042 3.25391 11.6337 3.85288 11.3909 4.41948Z\" fill=\"#00A000\"></path>\n<path d=\"M3.3601 17.1921C3.37629 18.4063 2.74494 19.0862 2.12977 18.5034C1.32034 17.7264 1.30416 15.3466 2.34022 15.2495C3.06871 15.3305 3.34391 16.4798 3.3601 17.1921Z\" fill=\"#00A000\"></path>\n<path d=\"M27.6917 9.24369C27.9993 10.2798 27.4812 10.9435 26.688 10.5226C25.6519 9.97217 25.1177 7.91622 25.9433 7.64102C25.9919 7.62483 26.0728 7.62483 26.1214 7.60864C26.8984 7.6734 27.4974 8.59614 27.6917 9.24369Z\" fill=\"#00A000\"></path>\n<path d=\"M29.5543 16.6256C29.4409 17.9045 28.6153 18.6006 28.0649 17.8883C27.4012 17.0303 27.6764 14.8287 28.6801 14.7153C29.3924 14.7801 29.619 15.8809 29.5543 16.6256Z\" fill=\"#00A000\"></path>\n<path d=\"M6.01558 24.218C6.03177 24.2666 6.43648 25.3674 5.72419 25.4483C4.68812 25.3674 3.49017 23.3924 4.10533 22.7772C4.20246 22.6801 4.31578 22.6639 4.41292 22.6477C5.10902 22.6963 5.75656 23.4895 6.01558 24.218Z\" fill=\"#00A000\"></path>\n<path d=\"M16.5051 29.5441C16.2946 30.2887 15.2909 30.5154 14.87 29.706C14.611 29.2041 14.8862 28.6213 15.6633 28.5728C16.3432 28.6051 16.6346 29.0908 16.5051 29.5441Z\" fill=\"#00A000\"></path>\n<path d=\"M20.7967 28.4756C20.5538 28.7831 19.9711 29.2688 19.4206 29.285C18.7407 29.2364 18.9512 28.2813 19.6311 27.7147C20.0682 27.3424 20.4405 27.3262 20.57 27.3262C21.2176 27.3747 21.2176 27.9575 20.7967 28.4756Z\" fill=\"#00A000\"></path>\n<path d=\"M19.8739 2.15321C20.0682 2.41223 20.1815 2.81694 19.6797 2.84932C18.8217 2.80076 18.1741 1.7485 18.5141 1.48948C18.5626 1.44092 18.6274 1.44092 18.6922 1.44092C19.0969 1.45711 19.6311 1.82944 19.8739 2.15321Z\" fill=\"#00A000\"></path>\n<path d=\"M13.8509 1.66741C13.5433 2.29876 12.653 2.54159 12.4749 2.15307C12.313 1.74835 13.09 1.08462 13.6243 1.05225C13.9642 1.05225 13.9966 1.37602 13.8509 1.66741Z\" fill=\"#00A000\"></path>\n<path d=\"M6.12972 5.87644C5.54693 6.75062 4.76988 7.07439 4.67275 6.6373C4.55943 6.11927 5.57931 4.77562 6.2916 4.72705C6.76107 4.77562 6.38874 5.48791 6.12972 5.87644Z\" fill=\"#00A000\"></path>\n<path d=\"M23.3061 3.67478C23.5165 3.93379 23.7594 4.45183 23.2413 4.4842C22.3348 4.40326 21.4282 3.0758 21.7196 2.80059C21.7682 2.75203 21.8329 2.75203 21.8977 2.73584C22.351 2.76822 22.9661 3.23768 23.3061 3.67478Z\" fill=\"#00A000\"></path>\n<path d=\"M2.97199 9.87496C2.92343 9.98828 2.51871 10.9596 2.00068 11.0082C1.33695 10.911 2.00068 9.01696 2.69679 8.56368C2.81011 8.48274 2.87486 8.48274 2.93962 8.46655C3.34433 8.53131 3.18244 9.34073 2.97199 9.87496Z\" fill=\"#00A000\"></path>\n<path d=\"M30.3314 11.7206C30.4124 12.1253 30.4448 12.8861 30.0401 12.9347C29.2792 12.8376 28.8421 10.7007 29.2792 10.3284C29.3278 10.2798 29.3925 10.2798 29.4249 10.2798C29.862 10.3445 30.2181 11.154 30.3314 11.7206Z\" fill=\"#00A000\"></path>\n<path d=\"M2.47043 21.7897C2.66469 22.421 2.63231 23.0362 2.27616 22.8743C1.61243 22.5829 0.916326 20.5432 1.43436 20.3975H1.48293C1.88764 20.446 2.30854 21.2393 2.47043 21.7897Z\" fill=\"#00A000\"></path>\n<path d=\"M28.3552 23.8296C27.9343 24.5581 27.2705 25.0923 27.141 24.6714C26.9629 24.121 27.8209 22.5831 28.4523 22.5183C28.8246 22.5669 28.6951 23.2306 28.3552 23.8296Z\" fill=\"#00A000\"></path>\n<path d=\"M10.1606 29.544C10.4035 29.8031 10.5977 30.1268 10.3225 30.1268C9.7883 30.143 8.37989 29.1555 8.63891 28.7994C8.67129 28.7508 8.73604 28.7346 8.8008 28.7346C9.31883 28.767 9.9178 29.285 10.1606 29.544Z\" fill=\"#00A000\"></path>\n<path d=\"M24.9563 27.4396C24.7296 27.6987 24.1792 28.1681 23.7583 28.2005C23.305 28.1519 23.9202 27.213 24.5192 26.7435C24.9239 26.4198 25.1505 26.4036 25.2315 26.4036C25.62 26.4521 25.3933 26.9702 24.9563 27.4396Z\" fill=\"#00A000\"></path>\n<path d=\"M13.1878 30.6613C13.2849 30.7746 13.5115 31.0498 13.2525 31.0822C12.7183 31.0822 11.6822 30.4346 11.9413 30.1756C11.9898 30.127 12.0708 30.1108 12.1193 30.1108C12.5564 30.1108 13.0097 30.467 13.1878 30.6613Z\" fill=\"#00A000\"></path>\n<path d=\"M17.7192 30.7906C17.5735 30.9201 17.2497 31.1305 16.9745 31.1467C16.6346 31.1305 16.8612 30.661 17.1202 30.4344C17.2983 30.2887 17.4764 30.2078 17.6868 30.2078C18.0592 30.2401 17.9944 30.5315 17.7192 30.7906Z\" fill=\"#00A000\"></path>\n<path d=\"M9.64113 2.73581C9.544 2.83294 8.99359 3.35097 8.52412 3.38335C8.16798 3.35097 8.39462 2.94626 8.81552 2.59011C9.04216 2.39585 9.56019 2.02351 9.93253 2.00732C10.3211 2.0397 9.67351 2.70343 9.64113 2.73581Z\" fill=\"#00A000\"></path>\n<path d=\"M16.9275 0.890291C17.0894 1.23025 16.7332 1.40832 16.3933 1.27882C15.94 1.10074 15.9076 0.598897 16.1666 0.469389C16.2152 0.4532 16.2476 0.437012 16.2961 0.437012C16.5552 0.4532 16.8304 0.67984 16.9275 0.890291Z\" fill=\"#00A000\"></path>\n<path d=\"M26.6083 5.5365C26.9644 6.03834 26.9806 6.42687 26.6407 6.3783C26.0741 6.29736 25.0056 4.88896 25.2808 4.59756C25.3132 4.56519 25.3618 4.56519 25.3941 4.56519C25.7989 4.59756 26.3493 5.14797 26.6083 5.5365Z\" fill=\"#00A000\"></path>\n<path d=\"M0.689784 14.2135C0.641218 14.6182 0.51171 15.3143 0.252693 15.3629C-0.232963 15.2658 0.0746191 13.1127 0.39839 12.9023L0.463144 12.8699C0.738349 12.9184 0.754538 13.7279 0.689784 14.2135Z\" fill=\"#00A000\"></path>\n<path d=\"M30.816 19.4909C30.6217 20.2517 30.2656 20.7374 30.1037 20.446C29.877 19.9927 30.2656 18.2767 30.7189 18.1958C30.9779 18.2444 30.9617 18.9081 30.816 19.4909Z\" fill=\"#00A000\"></path>\n<path d=\"M6.7129 27.6823C7.02048 28.0384 7.21474 28.3784 6.93954 28.346C6.38913 28.2651 5.17499 27.0024 5.46638 26.8243L5.54732 26.8081C5.91966 26.8567 6.45388 27.3747 6.7129 27.6823Z\" fill=\"#00A000\"></path>\n<path d=\"M21.0704 29.8516C20.6171 30.1592 20.002 30.402 20.002 30.2239C20.0181 30.0458 20.8923 29.2526 21.4427 29.2202C21.7179 29.2526 21.4751 29.5278 21.2808 29.6897C21.2485 29.7059 21.1675 29.7868 21.0704 29.8516Z\" fill=\"#00A000\"></path>\n<path d=\"M15.2925 31.163C15.3735 31.3249 15.3249 31.4544 14.9849 31.3573C14.6612 31.2601 14.4993 31.0497 14.6612 30.9525L14.7583 30.9202C15.0173 30.8716 15.2116 31.0173 15.2925 31.163Z\" fill=\"#00A000\"></path>\n<path d=\"M12.8303 0.469616C12.3932 0.744822 12.0695 0.809576 12.1018 0.712445C12.1342 0.534371 12.9113 0.194411 13.1541 0.178223C13.1865 0.178223 13.235 0.178223 13.1217 0.275354C13.057 0.32392 12.9436 0.404862 12.8303 0.469616Z\" fill=\"#00A000\"></path>\n<path d=\"M15.3237 0.161885C15.2913 0.22664 15.178 0.339959 14.9999 0.356148C14.8542 0.339959 14.8704 0.242828 14.9676 0.145697C15.0485 0.0809427 15.1942 0 15.2913 0C15.4208 0.0161885 15.3237 0.161885 15.3237 0.161885Z\" fill=\"#00A000\"></path>\n<path d=\"M0.608603 18.9245C0.721923 19.4587 0.721923 19.8148 0.64098 19.7663C0.430529 19.653 0.0743813 17.8884 0.236267 17.8398C0.333398 17.8884 0.495283 18.4226 0.608603 18.9245Z\" fill=\"#00A000\"></path>\n<path d=\"M29.3427 7.9001C29.537 8.24006 29.6503 8.58002 29.4884 8.53145C29.2132 8.45051 28.4847 7.20399 28.679 7.12305H28.6952C28.8571 7.17161 29.1485 7.56014 29.3427 7.9001Z\" fill=\"#00A000\"></path>\n<path d=\"M3.61909 25.3512C3.66766 25.4159 4.03999 25.934 3.92667 25.9663C3.66766 25.9178 2.68015 24.6389 2.84204 24.5417H2.85823C3.00392 24.5903 3.40864 25.0598 3.61909 25.3512Z\" fill=\"#00A000\"></path>\n<path d=\"M18.1414 0.259053C18.3519 0.339996 18.449 0.40475 18.4166 0.420939C18.3357 0.485693 17.4939 0.194299 17.4453 0.113357L17.4615 0.097168C17.5748 0.113357 17.8986 0.178111 18.1414 0.259053Z\" fill=\"#00A000\"></path>\n<path d=\"M2.43813 7.4629C2.35719 7.57622 2.11436 7.96474 2.01723 8.01331C1.87153 7.96474 2.60002 6.88011 2.71334 6.83154H2.72952C2.81047 6.86392 2.4867 7.39814 2.43813 7.4629Z\" fill=\"#00A000\"></path>\n<path d=\"M5.67515 3.78798C5.319 4.12794 5.09236 4.25745 5.07617 4.1765C5.07617 4.03081 5.82084 3.31851 6.06367 3.28613C6.17699 3.28613 5.90179 3.57753 5.67515 3.78798Z\" fill=\"#00A000\"></path>\n<path d=\"M21.0058 1.03617C21.2648 1.18187 21.3944 1.29519 21.3134 1.31138C21.1515 1.34376 20.0993 0.777157 20.1802 0.712402H20.2126C20.3745 0.728591 20.763 0.890476 21.0058 1.03617Z\" fill=\"#00A000\"></path>\n<path d=\"M24.6005 2.81684C24.8919 3.04348 25.0376 3.22156 24.9243 3.22156C24.7139 3.23775 23.4835 2.33119 23.613 2.25024H23.6454C23.8721 2.29881 24.3091 2.5902 24.6005 2.81684Z\" fill=\"#00A000\"></path>\n<path d=\"M9.69156 1.31126C9.57824 1.37602 9.23828 1.55409 9.18971 1.52171C9.17352 1.42458 9.9182 1.06843 10.0801 1.05225C10.0963 1.10081 9.75631 1.27889 9.69156 1.31126Z\" fill=\"#00A000\"></path>\n</svg>\n<img src=\"https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif\"/>\n</div>\n<div>\n<label>\n<span></span>\n</label>\n<h3></h3>\n<div></div>\n<div>\n<form method=\"post\">\n<input type=\"hidden\" value=\"\"/>\n<input type=\"hidden\" value=\"\"/>\n<input type=\"hidden\" value=\"\"/>\n<input type=\"hidden\" value=\"free\"/>\n<input placeholder=\"Email Address\" required=\"\" type=\"email\" value=\"\"/>\n<button>Submit</button>\n</form>\n</div>\n</div>\n</div>\n</div>\n<div>\n<hr/>\n<p>Article printed from InvestorPlace Media, https://investorplace.com/2023/04/novavax-outlook-why-nvax-stock-could-12x-in-the-next-12-months/.</p>\n<p>©2023 InvestorPlace Media, LLC</p>\n</div>\n<div></div>\n<div>\n<div>\n<h2>Sponsored Headlines</h2>\n</div>\n<div>\n<ins></ins>\n</div>\n</div>\n</div></body></html>","source":"investorplace","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Outlook: Why NVAX Stock Could 12X in the Next 12 Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Outlook: Why NVAX Stock Could 12X in the Next 12 Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-13 00:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2023/04/novavax-outlook-why-nvax-stock-could-12x-in-the-next-12-months/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Recent, positive clinical data released by Novavax (NVAX) indicates that NVAX stock could surge almost 12 times in the next year.The company’s drugs could attain meaningful shares of the Covid-19 ...</p>\n\n<a href=\"https://investorplace.com/2023/04/novavax-outlook-why-nvax-stock-could-12x-in-the-next-12-months/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HRMY":"Harmony Biosciences Holdings, Inc.","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4568":"美国抗疫概念","BK4588":"碎股","BK4007":"制药","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2023/04/novavax-outlook-why-nvax-stock-could-12x-in-the-next-12-months/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2327189187","content_text":"Recent, positive clinical data released by Novavax (NVAX) indicates that NVAX stock could surge almost 12 times in the next year.The company’s drugs could attain meaningful shares of the Covid-19 vaccine and flu shot markets.NVAX stock could easily undergo a huge short squeeze. \n\n\n\n \n\nSource: Ascannio/Shutterstock.com\n\n\n\nAfter recently reporting strong clinical data, Novavax (NASDAQ:NVAX) has tremendous opportunities in front of it. More specifically, the company’s coronavirus booster and its coronavirus-flu combination vaccine can become huge revenue generators. Given these points, I believe that NVAX stock can soar almost 12 times within the next year.\nThe company’s new CEO also makes me very upbeat about the stock’s outlook. Moreover, the NVAX stock has a very high short interest, and a strong rebound is underway.\n\n\n\nNVAX\nNovavax\n$9.07\n\n\n\n\n\n\n\n\n\nStrong Clinical Data Gives Novavax a Huge Opportunity\nData unveiled by Novavax on April 5 showed that a single booster dose of its Covid-19 shot generated “immune responses [that] were comparable to three total doses of the approved messenger RNA (mRNA) vaccines. “\nThe fact that one dose of Novavax’s vaccine generated a “comparable” response to three shots of the mRNA vaccines should lead some doctors to recommend that their patients get Novavax’s vaccine instead of the mRNA jabs.\nMeanwhile, data indicate that high percentages of the populations of other developed countries have yet to receive boosters. For example, in the U.S., as of last month, only 34 boosters had been administered per 100 people. In the U.K., that figure is 60, in France, it’s 71, and in Germany, it’s 78.\nRemember that if the entire population had received three booster shots each, 300 booster shots per 100 people would be administered.\nRegarding Novavax’s combined flu-Covid vaccine, the company reported that the job had elicited effective responses against both the coronavirus and “and multiple influenza strains.,” PharmaLive.com said.\nMoreover, the combination shot was as safe as taking Novavax’s flu shot and coronavirus jab separately.\n\n\n\n\n\n\nWhy NVAX Stock Can Soar Almost 12 Times\nAccording to Statista, global revenue from the coronavirus vaccine is expected to reach $26 billion next year. Let’s say that Novavax gets 15% of that revenue. That equates to $3.9 billion.\nMeanwhile, revenue from flu vaccines came in at $4.28 billion in 2022. Let’s say the market grows to $4.5 billion next year, and Novavax gets 10% of that revenue. That works out to another $450 million.\nIf the drug maker meets these forecasts and gets a price-sales ratio of just two, its market capitalization would be $8.7 billion. That’s nearly 12 times its current market capitalization of $729 million.\nBut to make this forecast a reality, the company has to greatly step up its marketing efforts, both to doctors and consumers. It remains to be seen if it can do so. Still, with the firm under the leadership of a new, highly accomplished CEO, John Jacobs, I think it may indeed be able to do what’s necessary on the marketing front to at least come close to meeting my projections.\n\n\n\n\n\n\nThree Other Reasons to Be Bullish on NVAX Stock\nSpeaking of the company’s new CEO, Jacobs, as I wrote earlier, has an excellent resume. Specifically, he was CEO of Harmony Biosciences (NASDAQ:HRMY) from 2018 until the beginning of 2023. During his tenure, Harmony launched a successful IPO in 2020, and its stock price climbed from $35 when it started trading to $53 just before it was announced that Jacobs was leaving.\nAlso, during his stint as CEO, the FDA approved the company’s narcolepsy treatment, Wakix. While a short seller has recently alleged that Harmony covered up the deaths of 12 patients who were taking the drug during clinical trials of the treatments, investment bank Raymond James, as well as Harmony itself, have denied the charges, with the bank writing that “Wakix’s safety profile is not an issue based on our own diligence with prescribers.” Moreover, Goldman Sachs recently named Harmony one of the stocks it believes are best positioned to avoid a recession.\nIn any event, the fact that Jacobs would choose to become CEO of Novavax after his successful tenure at Harmony suggests that Novavax’s prospects are strong. Moreover, Jacobs’ experience should be an asset for Novavax and NVAX stock going forward.\nAlso positive for the shares are its high short interest (nearly 40% of NVAX stock was being sold short as of April 6) and the fact that the Street seems to have viewed the data the company released on April 5 positively. As evidence of the latter point, NVAX stock jumped from $7.34 as of the close of trading on April 4 to $8.46 as of the market close on April 6.\nAs of the date of publication, Larry Ramer owned shares of NVAX. He may purchase shares of Eisai during the week of April 10. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.\n\nLarry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been PLUG, XOM and solar stocks. You can reach him on Stocktwits at @larryramer.\n\n\nBiotech, Healthcare, Technology\n\n\nUndervalued Stocks\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubmit\n\n\n\n\n\n\n\nArticle printed from InvestorPlace Media, https://investorplace.com/2023/04/novavax-outlook-why-nvax-stock-could-12x-in-the-next-12-months/.\n©2023 InvestorPlace Media, LLC\n\n\n\n\nSponsored Headlines","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}